ABOUT BioCrowd

Mission

BioCrowd accelerates lifesaving research by modernizing how clinical and translational science is funded—so institutions can move proof-of-concept programs forward when traditional grant timelines and budgets fall short.

Why BioCrowd

Research institutions are facing growing funding uncertainty and longer cycles to secure capital. BioCrowd provides clinical research funding infrastructure that helps hospitals, universities, and patient foundations launch milestone-based campaigns supported by donor-advised funds, venture philanthropy, and impact-aligned capital.

What this means for you

  • For Institutions: Faster proof-of-concept funding, donor engagement, and milestone-based reporting
  • For Funders: Tax-efficient giving and transparent progress tracking
  • For Patient Communities: A clearer path to move priority research toward clinical outcomes

The BioCrowd Team

Skilled . Educated . Experienced

BioCrowd is led by experienced operators across healthcare, biotech, finance, and technology—with deep experience in academic research ecosystems and commercialization pathways. We combine institutional rigor with modern funding rails to help science reach patients faster.

Mark Stoner

(CEO) Cofounder

30+ years across enterprise technology and blockchain, including Accenture and PwC experience, and leadership across large-scale digital initiatives. Mark focuses on institutional

Solenn Thircuir

PhD (CSO)

Cancer researcher with experience across rare disease networks and applied AI in biomedical contexts. Solenn leads scientific diligence, project selection, and translational strategy to ensure campaigns align with real clinical milestones.

Shahed Iqbal

MBBS, PhD

Executive Director and Head of Molecular Epidemiology & Clinical Data Sciences at Gilead; former CDC senior advisor. Shahed supports BioCrowd’s clinical credibility, evidence strategy, and real-world data alignment.

Srini Belligundu

(CTO)

Product and engineering leader with experience across GenAI/ML and platform development. Srini leads BioCrowd’s product execution, security, and scalable infrastructure for campaign management and reporting.

Angelo Masullo

(Finance)

Experience in financial modeling, venture finance strategy, and digital asset markets. Angelo supports BioCrowd’s campaign financial structures and institutional-grade analytics for funders and partners.

Team

John Connelly

Senior Advisor

Serial entrepreneur and investor with decades of experience across IT and healthcare, including multiple successful exits. John advises BioCrowd on company strategy, scaling, and enterprise partnerships.

Emmanuel Gomez, PharmD, MSc, Executive MBA

Senior Advisor

CEO | INATHERYS
CEO at INATHERYS with 15+ years bridging academia and biopharma, including senior roles at Institut Curie and Institut Carnot CALYM. Emmanuel supports BioCrowd’s academic-to-industry partnership strategy and commercialization pathways.

Prentice Tom, MD

MD Senior Advisor

Healthcare executive leading innovations in care delivery, with leadership experience across major clinical organizations. Prentice advises BioCrowd on health system alignment, adoption, and clinical operations realities.

Cristina Puchades, PhD (Biophysics)

Senior Advisor

Scientist with 10+ years across biotech/pharma and academia (including J&J, Scripps, UCSF). Cristina supports BioCrowd’s research evaluation approach and translational readiness assessment.

Why BioCrowd Is Different

Institution-first, not protocol-first

We start with your strategic priorities, not pre-designed protocols. Our aporoach ensureys alignment with your mission and ongoing initiatives.

Tailored Proof-of-Concept (POC)

Bridge Between Academic Rigor & Emerging Technologies

Smart Partnering, Not Just Smart Contracts

Visibility & Credibility

Built by Researchers, for Researchers

We co-develop a POC project that reflects your institution's real-world needs-whether it's for translational research, clinical trial coordination, or public-private collaboration

We help you explore new funding models (Web3, blockchain, DAOs) without compromising academic standards or compliance

Our model encourages collaborative governance with your teams, embedding stakeholder insights into every phase.

We support early-stage projects not only with funding, but also with exposure to international partners, press visibility, and academic validation

We're not here to sell a tool-we're here to co-create a catalyst. Let's build something together that advances your institution's impact and inspires future models of research